5:28 PM
Mar 19, 2013
 |  BC Extra  |  Company News

UCB, Five Prime in discovery deal for inflammation and CNS disorders

UCB Group (Euronext:UCB) and Five Prime Therapeutics Inc. (South San Francisco, Calif.) partnered to discover drug targets and therapeutics for fibrosis-related inflammatory diseases and CNS disorders. Under the deal, UCB...

Read the full 137 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >